The SuperSeasonal Sunday Watchlist (May 11)

• Ticker: ALNY
• Seasonal frequency higher: 85.71%
• Profit factor: 20.61
• Annualized return: 109.07%
• Data since: 2004

Alnylam remains the most compelling setup on this week’s list.

The seasonal numbers are strong, but the bigger reason ALNY earns the top spot is that the current story supports the pattern. Alnylam recently reported a major quarter, with total revenue rising 96% year over year and AMVUTTRA revenue jumping 187% year over year to roughly $889.9 million.

That is the kind of news that can keep a stock on institutional radar.

For newer traders, here is the simple version: biotech stocks usually need a catalyst. A seasonal pattern by itself is useful, but a seasonal pattern plus fresh earnings strength, product momentum, and analyst attention is much more interesting.

AMVUTTRA is the center of the story. The drug is being used in ATTR-CM, a serious heart-related disease market, and the company’s recent results suggest demand is ramping quickly.

Plain-English takeaway:

ALNY is not a low-volatility idea. Biotech can move fast in both directions. But among this week’s seasonal candidates, it has the best combination of historical strength, fresh earnings momentum, and a clear product-growth story.

For exact timing and exit-window details, readers can log in to SuperSeasonal.com .

The company is best known for structural heart products, especially TAVR, or transcatheter aortic valve replacement. In plain English, Edwards makes advanced medical devices used to treat serious heart valve disease.

The seasonal profile is excellent. EW has shown a historical frequency higher of nearly 88.5% during this seasonal window, with a strong profit factor above 50.

The business backdrop also helps. Edwards recently reported first-quarter sales growth of 16.7% to $1.65 billion, with TAVR sales up 14.4% to $1.20 billion. The company also raised its 2026 sales-growth guidance.

That is exactly the kind of combination traders like to see: a stock with a strong seasonal setup and a company that just gave the market a better outlook.

Plain-English takeaway:

EW is not as explosive as ALNY, but it may be cleaner for traders who prefer a higher-quality healthcare name with less biotech headline risk. The seasonal stats are strong, and the recent guidance raise gives the pattern a believable business driver.

For exact timing and exit-window details, readers can log in to SuperSeasonal.com .

• Ticker: NRG
• Seasonal frequency higher: 81.82%
• Profit factor: 11.10
• Annualized return: 67.66%
• Data since: 2003

NRG is the third stock on this week’s list.

This is a different kind of setup. NRG is not a software stock, a biotech stock, or a classic consumer-growth story. It is an energy and power-generation company — and that makes it timely.

One of the biggest themes in the market right now is electricity demand. Artificial intelligence, data centers, reshoring, and grid reliability are all increasing investor interest in companies tied to power generation and flexible energy supply.

NRG fits that theme. Earlier this year, the company completed the acquisition of 13 gigawatts of power-generation assets and CPower’s commercial and industrial virtual power plant platform from LS Power. NRG said the deal doubled its generation capacity and strengthened its ability to serve homes and businesses amid rising energy needs.

That gives traders a real “why” behind the seasonal setup.

NRG’s seasonal stats are not as clean as ALNY or EW, but they are still attractive. The stock has historically moved higher more than 81% of the time during this window, with a 67.66% annualized return profile.

Plain-English takeaway:

NRG brings a fresh theme to the newsletter: power demand. Instead of another tech name, NRG gives readers exposure to the infrastructure side of the AI story — the electricity needed to keep all those chips, servers, and data centers running.

For exact timing and exit-window details, readers can log in to SuperSeasonal.com .